Yahoo
NYSE - Delayed Quote USD

DaVita Inc. (DVA)

197.10 +2.18 (+1.12%)
At close: May 28 at 4:00:02 PM EDT
197.07 -0.03 (-0.02%)
Pre-Market: 8:51:04 AM EDT
Trade DaVita on Coinbase
Chart Range Bar
Loading chart for DVA

News headlines DaVita Inc. (DVA) has gained significant attention, recently being named Zacks' Bull of the Day due to a 70% year-to-date rallyand robust earnings growth projections. The company continues to focus on community care and workforce initiatives while facing challenges from reimbursement pressures in the dialysis market.

DaVita Inc. (DVA) has gained significant attention, recently being named Zacks' Bull of the Day due to a 70% year-to-date rallyand robust earnings growth projections. The company continues to focus on community care and workforce initiatives while facing challenges from reimbursement pressures in the dialysis market.

Updated 4m ago · Powered by Yahoo Scout
  • Previous Close 194.92
  • Open 193.83
  • Bid --
  • Ask --
  • Day's Range 193.84 - 198.60
  • 52 Week Range 101.00 - 202.69
  • Volume 367,404
  • Avg. Volume 869,659
  • Market Cap (intraday) 12.651B
  • Beta (5Y Monthly) 0.84
  • PE Ratio (TTM) 18.97
  • EPS (TTM) 10.39
  • Earnings Date (est.) Aug 5, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 193.71

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

www.davita.com

78,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Performance Overview

Trailing total returns as of 5/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DVA
73.49%
S&P 500 (^GSPC)
10.49%

1-Year Return

DVA
44.23%
S&P 500 (^GSPC)
28.45%

3-Year Return

DVA
109.06%
S&P 500 (^GSPC)
79.85%

5-Year Return

DVA
64.15%
S&P 500 (^GSPC)
79.91%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 3.42B
Earnings 197.53M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
1B
2B
3B

Analyst Insights

View More

Analyst Price Targets

145.00 Low
193.71 Average
197.10 Current
235.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/11/2026
Analyst TD Cowen
Rating Action Maintains
Rating Hold
Price Action Raises
Price Target 144 -> 201

Statistics

View More

Valuation Measures

Annual
As of 5/28/2026
  • Market Cap

    12.65B

  • Enterprise Value

    25.21B

  • Trailing P/E

    18.99

  • Forward P/E

    13.59

  • PEG Ratio (5yr expected)

    0.61

  • Price/Sales (ttm)

    1.04

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    1.82

  • Enterprise Value/EBITDA

    9.31

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.65%

  • Return on Assets (ttm)

    7.50%

  • Return on Equity (ttm)

    80.98%

  • Revenue (ttm)

    13.84B

  • Net Income Avi to Common (ttm)

    756.42M

  • Diluted EPS (ttm)

    10.39

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    666.55M

  • Total Debt/Equity (mrq)

    1,261.33%

  • Levered Free Cash Flow (ttm)

    999.66M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

197.10 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Raising target price to $215.00

    DAVITA INC has an Investment Rating of BUY; a target price of $215.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
  • Lowering target price to $214.00

    DAVITA INC has an Investment Rating of BUY; a target price of $214.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target
  • Daily – Vickers Top Buyers & Sellers for 05/14/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Raising target price to $221.00

    DAVITA INC has an Investment Rating of BUY; a target price of $221.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of High; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: